Metal related neurodegenerative disease /

This issue reviews the role of metals in neurodegenerative diseases; including Parkinson's and Huntington's disease; restless leg syndrome and NBIA disorders; and Wilson's disease and manganese and calcium accumulation disorders. An update on advances in neuroimaging and pathology of...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Bhatia, Kailash (Editor ), Schneider, Susanne A. (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Amsterdam : Elsevier, 2013.
Colección:International review of neurobiology ; v. 110.
Temas:
Nervous system > Degeneration.
Metal ions > Physiological effect.
Molecular neurobiology.
Chemistry, Metallurgic.
Ions m�etalliques > Effets physiologiques.
Neurobiologie mol�eculaire.
M�etallurgie extractive.
Chemistry, Metallurgic
Metal ions > Physiological effect
Molecular neurobiology
Nervous system > Degeneration
Acceso en línea:Texto completo
Texto completo
Tabla de Contenidos:
  • Front Cover; Metal Related Neurodegenerative Disease; Copyright; Contents; Contributors; Preface; Editorial: Metal-Related Neurological Disorders: Several New Genes and Better Understanding; Reference; Chapter One: The Relevance of Metals in the Pathophysiology of Neurodegeneration, Pathological Considerations; 1. Introduction; 2. The Role of Specific Metals in Neurodegeneration; 2.1. The role of iron; 2.1.1. Alzheimer disease; 2.1.2. Parkinson disease; 2.1.3. Multiple sclerosis; 2.1.4. Other neurodegenerative disorders; 2.2. The role of aluminum; 2.3. The role of copper
  • 2.4. The role of zinc2.5. The role of manganese; 3. Conclusions and Future Perspectives; References; Chapter Two: Pantothenate Kinase-Associated Neurodegeneration (PKAN) and PLA2G6-Associated Neurodegeneration (PLAN): Revi ...; 1. Introduction; 2. Pantothenate Kinase-Associated Neurodegeneration; 2.1. Clinical presentation; 2.1.1. Onset of clinical symptoms; 2.1.2. Clinical disease features; 2.1.3. Disease course; 2.2. Neuroimaging features in PKAN (Fig.2.1); 2.3. Neuropathological features of PKAN; 2.4. Molecular genetics of PKAN; 2.5. Pathophysiological disease mechanisms in PKAN
  • 2.6. Management of PKAN treatment2.6.1. Clinical assessment; 2.6.2. Treatment strategies; 2.6.3. Spasticity and dystonia; 2.6.4. Multidisciplinary team input; 2.6.5. New experimental therapies under consideration (see Chapter 7); 2.6.5.1. Iron chelation (see Chapter 7); 2.6.5.2. Pantothenate; 3. PLA2G6-Associated Neurodegeneration; 3.1. Clinical features of PLAN; 3.1.1. Disease onset; 3.1.2. Disease clinical features; 3.1.3. Disease course; 3.1.4. Electrophysiological investigations in PLAN; 3.2. Neuroimaging features of PLAN (Fig.2.3); 3.3. Neuropathological features of PLAN
  • 3.4. Molecular genetic features of PLAN3.5. Pathogenic disease mechanisms in PLAN; 3.6. Management of PLAN; 3.6.1. Clinical assessment; 3.6.2. Multidisciplinary team input; 3.6.3. New experimental therapies under consideration (see Chapter 7); 3.6.4. PLA2G6-dystonia parkinsonism; 3.6.5. Treatment strategies; 3.6.5.1. For INAD and atypical NAD; 4. Conclusion; Acknowledgments; References; Chapter Three: Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN); 1. Introduction; 2. Clinical Findings; 3. Neuroimaging; 4. Neuropathology; 5. Genetics; 6. Conclusion; Acknowledgments

Ejemplares similares